Get the Finder app 🥳

Track your credit score

Free

How to buy Starpharma Holdings shares | A$1.46

Own Starpharma Holdings shares in just a few minutes.

Posted

Fact checked

We’re committed to our readers and editorial independence. We don’t compare all products in the market and may receive compensation when we refer you to our partners, but this does not influence our opinions or reviews. Learn more about Finder.

Starpharma Holdings Limited is a biotechnology business based in Australia. Starpharma Holdings shares (SPL) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $1.46 – a decrease of 2.01% over the previous week. Starpharma Holdings has a trailing 12-month revenue of around $6.6 million.

How to buy shares in Starpharma Holdings

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Starpharma Holdings . Find the share by name or ticker symbol: SPL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Starpharma Holdings reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of $1.46, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Starpharma Holdings . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Starpharma Holdings 's share price?

Since the stock market crash in March caused by coronavirus, Starpharma Holdings 's share price has had significant positive movement.

Its last market close was $1.46, which is 16.44% up on its pre-crash value of $1.22 and 137.40% up on the lowest point reached during the March crash when the shares fell as low as $0.615.

If you had bought $1,000 worth of Starpharma Holdings shares at the start of February 2020, those shares would have been worth $579.40 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,253.22.

Starpharma Holdings share price

Use our graph to track the performance of SPL stocks over time.

Starpharma Holdings shares at a glance

Information last updated 2020-10-21.
Latest market closeAUDA$1.46
52-week rangeAUDA$0.645 - AUDA$1.95
50-day moving average AUDA$1.579
200-day moving average AUDA$1.2025
Target priceAUDA$1.44
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) AUDA$-0.04

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

  • Brokerage - AU shares: From AUD 5 or 0.05%
  • Brokerage - US shares: USD 0
  • Sign-up process: Instant
  • Support - After hours: Yes
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD 8 or 0.1%
AUD 50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
Superhero share trading
AUD 5
No
ASX shares
Pay zero brokerage on all Australian ETFs.
Trade ASX stocks with a flat $5 commission fee and a low minimum investment of just $100.
CMC Markets Stockbroking
AUD 11 or 0.1%
No
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
SelfWealth Share Trading (Basic account)
AUD 9.5
AUD 0
ASX shares
Trade ASX-listed shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
ANZ Share Investing
AUD 19.95
No
ASX shares, Global shares, Margin trading, Options trading
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or 0.11%
AUD 63.50 per year on the global markets account
ASX shares, Global shares, Options trading, US shares
loading

Compare up to 4 providers

Is it a good time to buy Starpharma Holdings stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Starpharma Holdings price performance over time

Historical closes compared with the close of A$1.46 on 2020-10-22

1 week (2020-10-22) 0%
1 month (2020-09-29) -9.03%
3 months (2020-07-29) 32.13%
6 months (2020-04-29) 41.75%
1 year (2019-10-29) 32.13%
2 years (2018-10-29) 2.10%
3 years (2017-10-27) 7.35%
5 years (2015-10-29) 116.30%

Starpharma Holdings financials

Revenue TTM $6.6 million
Gross profit TTM $5.7 million
Return on assets TTM -21.57%
Return on equity TTM -39.82%
Profit margin -221.86%
Book value 0.084
Market capitalisation $592 million

TTM: trailing 12 months

Starpharma Holdings share dividends

We're not expecting Starpharma Holdings to pay a dividend over the next 12 months.

Starpharma Holdings share price volatility

Over the last 12 months, Starpharma Holdings 's shares have ranged in value from as little as $0.645 up to $1.95. A popular way to gauge a stock's volatility is its "beta".

SPL.AU volatility(beta: 1.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Starpharma Holdings 's is 1.5579. This would suggest that Starpharma Holdings 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Starpharma Holdings overview

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site